Pfizer and Innovent diabetes GLP-1 drugs to enter China's national insurance
From January 1, GLP-1 drugs from Pfizer and Innovent will be reimbursed under China's state scheme for type 2 diabetes patients, Reuters reported citing the NHSA.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
China's National Healthcare Security Administration said on Saturday that GLP-1 drugs from Pfizer (ecnoglutide) and Innovent Biologics (mazdutide) will join the state insurance scheme from January 1 for patients with type 2 diabetes. Reuters reported the decision.
The move is a new challenge for Denmark's Novo Nordisk. Its Ozempic was added to the reimbursement list in 2022, while Eli Lilly's Mounjaro and Innogen's efsubaglutide alfa were added this year. Inclusion makes the drugs more widely available in a country of 1.4 billion people, though higher volumes usually come with lower prices.
Two Eli Lilly drugs for ulcerative colitis and Crohn's disease and a CAR-T therapy from JW Therapeutics will also be added. Reuters said Ozempic pen sales in greater China fell 7% in 2025 to about 5.4 billion Danish crowns ($850 million).
why it matters
For markets the key point is competition rather than the listing itself. China is Novo's largest market after the US, and more rivals plus state-backed pricing pressure could weigh on its regional revenue.
market impact
Novo Nordisk: more competition and likely lower prices in China weigh on regional sales
- Novo Nordisk pressure down — more rivals and lower prices in China pressure regional sales
tags
instruments
sources
- Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes — Reuters, 14 November 2026 at 06:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗